To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Zhenzhun Biotechnology (Shanghai) Co. Ltd., a digital PCR company, has recently completed a Series A financing round of over CNY 100 million, exclusively invested by Huiyuan Capital, a professional investment institution in the healthcare industry.

A review of adverse events following vaccination against COVID-19 with mRNA vaccines in the USA confirms that most side effects were mild and decreased substantially after one day.

Luminex, a DiaSorin company, said on Tuesday that it has received CE marking for its xMap NxTag Gastrointestinal Pathogen Panel (GPP), a molecular multiplex panel for the detection of 16 different pathogens.

A new viral transport medium that enables collection and rapid inactivation of the SARS-CoV-2 virus, and stabilizes viral RNA at ambient temperature for transportation and use in in vitro diagnostic testing procedures, is now available in Europe.

Chinese single-cell technology firm Singleron Biotechnologies said on Monday that it has acquired Singapore-based Proteona.

The updated prospectus shows that Adicon additionally disclosed financial data for 2021 and other content. According to the prospectus, Adicon's operating income in 2021 will be CNY 3.380 billion.

On March 2, the FTSE Russell Day announced the results of the quarterly audit changes of the FTSE China A50 and other indices.

One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells.

AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO).

Moderna and Thermo Fisher Scientific Inc.announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.